Loading
CART84 is an experimental CAR-T cell therapy from Gyala Therapeutics in phase 2 trials for acute myeloid leukaemia, aimed at CD3.
CART84 is a CAR-T cell therapy developed by Gyala Therapeutics. Its target is CD3 (the sponsor names CD84). The sponsor states: Autologous T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor, to recognise and kill CD84-expressing leukaemia cells. ClinicalTrials.gov describes the intervention as: GYA01 (CART84): autologous cell-based product containing CD3+ T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor (CAR). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute myeloid leukaemia. The largest, NCT07471789, plans to enrol 33 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Autologous T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor, to recognise and kill CD84-expressing leukaemia cells. Connects to CD3.
1.CART84 slips into a pocket on CD3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CART84" OR ABSTRACT:"CART84") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CART84, not a curated reading list.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.